Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Xilio Therapeutics, Inc. (NASDAQ: XLO)
XLO Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-25.10%
Analyst Rating:
BUY
Analyst Forecast (1yr):
71.90%
XLO Stock Analysis
XLO
PE Ratio:
XLO
PEG Ratio:
Not Available
XLO
Forward EPS Growth (12 month):
0.00%
XLO
PS Ratio:
0.9
XLO
PSG Ratio:
XLO
Forward Revenue Growth (12 month):
-20.70%
XLO Articles
No data was found